Variables | All patients | 150 < P/F ≤ 200 (A) | 100 < P/F≤ 150 (B) | 100 < P/F≤ 200 (A + B) | P/F ≤ 100 (C) | p | ||
---|---|---|---|---|---|---|---|---|
A vs. B | B vs. C | A + B vs. C | ||||||
N | 128 | 29 | 68 | 97 | 31 | |||
Age, median [IQR], y | 66,5 [58–73] | 65 [54–72] | 68 [59–72] | 68 [59–72] | 66 [58–72] | 0.25 | 0.75 | 0.95 |
Sex: Male, n (%) | 81 (63.3) | 21 (72.4) | 42 (61.8) | 63 (64.9) | 18 (58.1) | 0.31 | 0.82 | 0.51 |
CCI, median [IQR] | 3 [2–4] | 2 [1–4] | 3 [2–4] | 3 [2–4] | 3 [2–4] | 0.141 | 0.28 | 0.64 |
Most relevant comorbidities | ||||||||
COPD, n (%) | 22 (17.2) | 6 (20.7) | 15 (22.1) | 21 (21.6) | 1 (3.2) | 0.88 | 0.02 | 0.025 |
Diabetes, n (%) | 32 (25.0) | 6 (20.7) | 17 (25.0) | 23 (23.7) | 9 (29.0) | 0.65 | 0.60 | 0.49 |
Arterial hypertension, n (%) | 78 (60.9) | 15 (51.7) | 47 (69.1) | 62 (63.9) | 16 (51.6) | 0.10 | 0.13 | 0.3 |
Obesity, n (%) | 23 (18.0) | 4 (13.8) | 10 (14.7) | 14 (14.4) | 9 (29.0) | 0.91 | 0.13 | 0.06 |
Chronic kidney disease, n (%) | 6 (4.7) | 1 (3.4) | 4 (5.9) | 5 (5.1) | 1 (3.2) | 0.61 | 1 | 1 |
History of cancer, n (%) | 4 (3.1) | 1 (3.4) | 1 (1.5 | 2 (2.1) | 2 (6.4) | 0.51 | 0.23 | 0.25 |
Ischemic heart disease, n (%) | 10 (7.8) | 3 (10.3) | 5 (7.3) | 8 (8.2) | 2 (6.4) | 0.69 | 1 | 1 |
Congestive heart failure, n (%) | 4 (3.1) | 1 (3.4) | 2 (2.9) | 3 (3.1) | 1 (3.2) | 1 | 1 | 1 |
Smoking, n (%) | 49 (38.3) | 10 (34.5) | 27 (39.7) | 37 (38.1) | 12 (38.7) | 0.63 | 0.42 | 0.95 |
Duration before admission, median [IQR] | 8 (5–10) | 8 (3–11) | 7 (5–10) | 8 (5–10) | 8 (5–10) | 0.88 | 0.98 | 0.99 |
Arterial blood gases on admission | ||||||||
PaO2, median [IQR], mmHg | 66,6 (58.9–76.1) | 68 (63.2–77.7) | 68.5 (59.9–78.7) | 68.05 (60.5–78) | 58.6 (52.8–67.5) | 0.94 | 0.82 | 0.80 |
PaCO2, median [IQR], mmHg | 33.6 (30.8–38.2) | 37 (33.5–39.5) | 33 (30–37) | 34.05 (31–38.1) | 33 (29.8–37.1) | 0.35 | 0.36 | 0.40 |
pH, median [IQR], | 7.46 (7.44–7.5) | 7.46 (7.45–7.49) | 7.46 (7.44–7.51) | 7.46 (7.44–7.5) | 7.49 (7.47–7.5) | 0.96 | 0.91 | 0.80 |
Lactates, median [IQR], mmol/L | 1 (0–1) | 0.8 (0.7–1.15) | 1.4 (1.05–1.7) | 1.2 (0.9–1.6) | 1.9 (1.5–2.35) | 0.60 | 0.63 | 0.79 |
Blood chemistry tests on admission | ||||||||
WBC, cells/µL | 8.04 (5.29–11.06) | 5.76 (4.13–10.15) | 8.69 (6.35–11.07) | 8.21 (5.26–11.06) | 9.33 (6.19–10.9) | 0.07 | 0.71 | 0.27 |
Lymphocytes, cells/µL | 800 (600–1120) | 780 (560–1260) | 800 (597–1032) | 800 (575–1090) | 750 (615–1124) | 0.49 | 0.99 | 0.85 |
CRP, mg/dl | 5.3 (2.58–12.8) | 9.5 (3.66–13.67) | 5.95 (2.38–11.9) | 6.5 (2.5–13.25) | 4.7 (2.58–8.96) | 0.09 | 0.54 | 0.27 |
PCT, ng/ml | 0.1 (0.04–0.27) | 0.1 (0.04–0.17) | 0.08 (0.03–0.33) | 0.09 (0.03–0.24) | 0.1 (0.06–0.5) | 0.41 | 0.16 | 1 |
eGFR, mL/min/1.73m2 | 87 (70–97) | 88 (73–97) | 83 (71–98) | 87.5 (71–98) | 85 (69–92) | 0.65 | 0.75 | 0.60 |
D-dimer, µg/L | 555 (288–1075) | 625 (267–977) | 455 (301–955) | 465 (285–1012) | 815 (300–1420) | 0.26 | 0.19 | 0.16 |
Na, mmol/L | 137 (135–139) | 136 (136–138) | 137 (135–139) | 137 (135–139) | 137 (135–139) | 0.91 | 0.87 | 0.87 |
Radiological imaging on admission | ||||||||
LUS | 16 (12–21) | 18 (11–22) | 16 (14–18) | 16 (14–20) | 15 (8–18) | 0.70 | 0.29 | 0.19 |
CT severity score | 12 (9–13) | 11 (9–12) | 12 (10–14) | 12 (9–13) | 11 (8–12) | 0.35 | 0.29 | 0.41 |